Advaxis Collaborates with NCI (OTC:ADXS)

Advaxis Inc (OTC:ADXS) has announced that they will be collaborating their Phase 2 trial with the Gynecologic Oncology Group which is a collaborative research of National Cancer Institute. The Company announced that they will be working together in a multicenter Phase II clinical trial of the Company’s lead drug candidate, ADXS11-001 in the treatment of advanced cervix cancer in women who have failed prior cytotoxic therapy. ADXS11-001 is a therapeutic vaccine that treats human papilloma virus (HPV) related tumors. Unlike marketed prophylactic vaccines that require treatment prior to exposure to the virus, ADXS11-001 treats patients who have already developed cancer as a result of HPV infection.

Advaxis Inc is a New Jersey-based pharmaceutical company that is developing attenuated live Lm vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer. The reason Advaxis is working on this research because as per the survey HPV is the most prevalent sexually transmitted disease in the US and the cause of cervix cancer, 40% of head and neck cancer, as well as penile, vulvar and anal cancer.

In the Phase 1 clinical trial, Advaxis has found that multiple doses of the agent were safely administered to this patient population at two (2) different dose levels and that the side effect profile, comprised of a flu-like syndrome, was consistent with strong immune stimulation. The Phase II trial will be conducted by GOG investigators and largely underwritten by the NCI and together both the teams will investigate greater statistical power of this vaccine.